Minerva Neurosciences NERV
NASDAQ NERV
$4.43 -0.26 (-5.54%)
At close: Sep 4, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017)

Minerva Neurosciences' (NERV) quarterly Non-Current Debt came in at $1.3 million in Q2 2017, down 78.69% YoY from $6.2 million in Q2 2016, and down 48.99% on a QoQ basis from $2.6 million in Q1 2017.

Analysis

Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017) Analysis & Trends

Minerva Neurosciences (NERV) has 3 years of Non-Current Debt data on file, last reported at $1.3 million in Q2 2017.

  • Quarterly Non-Current Debt fell 78.69% year-over-year to $1.3 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $1.3 million (down 78.69% YoY) and the FY2016 annual result came in at $3.8 million, down 54.83% from the prior year.
  • Non-Current Debt fell to $1.3 million in Q2 2017, from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $9.6 million in Q3 2015 to a low of $1.3 million in Q2 2017.
  • A 3-year average of $6.3 million and a median of $6.8 million in 2016 frame the typical range for Non-Current Debt.
  • Annual changes were most pronounced in 2016 — Non-Current Debt fell 22.74% — and 2017, when it tumbled 78.69%.
  • Tracing NERV's Non-Current Debt over 3 years: stood at $8.5 million in 2015, then sank by 54.83% to $3.8 million in 2016, then plunged by 65.47% to $1.3 million in 2017.
  • The last three Non-Current Debt figures came in at $1.3 million (Q2 2017), $2.6 million (Q1 2017), and $3.8 million (Q4 2016), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 882.16 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 8.96 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Minerva Neurosciences 207.37 Mn 207.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 1.33 Mn
Mar 31, 2017 2.60 Mn
Dec 31, 2016 3.84 Mn
Sep 30, 2016 5.05 Mn
Jun 30, 2016 6.23 Mn
Mar 31, 2016 7.38 Mn
Dec 31, 2015 8.50 Mn
Sep 30, 2015 9.61 Mn
Jun 30, 2015 8.70 Mn
Mar 31, 2015 9.55 Mn